In a recent discussion, I used the phrase “biotech wilderness periods” to describe the times of investor malaise around the sector, which result in its stock indices remaining range-bound. When I joined the fund management industry in the summer of 2000, it was just in time for a broad and lasting market sell-off that included biotech. The NASDAQ Biotech Index (NBI) had already started the retrenchment from its February 2000 high that was reached after publication of the first complete human genome DNA sequence drove hopes of a new era of drug development.
Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness
A Biotech Recovery May Be Some Way Off
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
